Profluent closed a $106 million financing round led by Altimeter Capital and Bezos Expeditions to scale large AI models for protein design across therapeutics, agriculture, and biomanufacturing. The company said its Protein Atlas contains over 115 billion proteins and highlighted partnerships with IDT and Revvity for enzyme and therapeutic enzyme discovery. The funding aims to accelerate platform R&D and commercial deployments, reflecting continued investor appetite for AI-native platforms that shorten protein design timelines.